GLP3-RT is a triple agonist peptide engineered to target the GLP-1, GIP, and glucagon receptors. By integrating these three metabolic pathways, it achieves synergistic effects on fat reduction and glycemic control that exceed those of single or dual agonists. GLP3-RT simultaneously suppresses appetite, enhances insulin sensitivity, and increases resting energy expenditure through glucagon receptor activation—a unique mechanism that promotes fat oxidation and significant liver fat reduction. In clinical trials, it has demonstrated unprecedented efficacy, including mean weight reductions of up to 28%, positioning it as a potent investigational research tool for obesity, type 2 diabetes, and metabolic-associated steatotic liver disease.
Categories: Lipolysis, Peptides
